top of page
Executive Spotlights

Biogen's $6.5B Acquisition of Reata: Powering Up Rare Disease Portfolio!

Cambridge, MA, July 28, 2023 (Reuters) -- Biogen (BIIB.O) has announced that it is acquiring Reata Pharmaceuticals (RETA.O), for almost $6.5 billion. This marks the first significant acquisition under the leadership of CEO Christopher Viehbacher, steering the drugmaker towards a path of growth.

Read full article here.

Recent Posts

See All
Life Science Headlines
bottom of page